Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Ventana Signs Companion Diagnostic Agreement for Genmab Antibody-Drug Conjugate

By BiotechDaily International staff writers
Posted on 14 Apr 2014
Ventana Medical Systems, Inc. (Ventana; Tucson, AZ, USA), a member of the Roche Group (Basel, Switzerland), has entered into an agreement with Genmab A/S (Copenhagen, Denmark) for the development of companion diagnostic (CDx) tools for Genmab's "HuMax-TF-ADC" antibody-drug conjugate (ADC) program. As part of the agreement, Ventana will provide its expertise and services towards the development of an immunohistochemistry (IHC) companion diagnostic test for the detection of tissue factor (TF) in patient tumor samples. The TF assay will be developed for possible designation as the screening test in clinical trials involving HuMax-TF-ADC.

CDx tests, designed to detect the presence of specific biomarkers, assist clinicians in selecting effective therapies and in identifying the patients most likely to respond favorably to specific therapies. Incorporating a companion diagnostic strategy into a drug development program may help generate more effective drugs with improved safety profiles for patients. Ventana has worked with more than 45 biopharmaceutical partners and is currently engaged in more than 180 collaborative projects to develop and commercialize companion diagnostics globally. The company has a global install base of over 10,000 automated platforms that run advanced cancer diagnostic tests.

Via antibody conjugation to potent cytotoxic drugs, ADCs for cancer therapy can increase efficacy and reduce systemic toxicity of drugs by targeting them selectively to tumor cells The targeted nature of ADCs make them good candidates for codevelopment with the Ventana IHC-based companion diagnostic assays that measure tumor-specific antigens.

"We are pleased to work with Genmab to develop a companion diagnostic for HuMax-TF-ADC," said Ventana President Mara G. Aspinall. "This agreement is in 100% alignment with our CDx strategy and our ever-growing lineup of global pharma partnerships designed to bring promising therapies to market faster to improve the lives of cancer patients."

Related Links:

Ventana Medical Systems
Genmab 
Roche



Channels

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.